Literature DB >> 11435264

Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia.

S Blomhoff1, T T Haug, K Hellström, I Holme, M Humble, H P Madsbu, J E Wold.   

Abstract

BACKGROUND: No controlled trial of treatment of generalised social phobia has been conducted in general practice. AIMS: To examine the efficacy of sertraline or exposure therapy, administered alone or in combination in this setting.
METHOD: Study was of a randomised, double-blind design. Patients (n = 387) received sertraline 50-150 mg or placebo for 24 weeks. Patients were additionally randomised to exposure therapy or general medical care.
RESULTS: Sertraline-treated patients were significantly more improved than non-sertraline-treated patients (chi(2)=12.53, P<0.001; odds ratio=0.534; 95% Cl 0.347-0.835). No significant difference was observed between exposure- and non-exposure-treated patients (chi(2)=2.18, P=0.140; odds ratio=0.732; 95% Cl 0.475-1.134). In the pairwise comparisons, combined sertraline and exposure (chi(2)=12.32; P<0.001) and sertraline (chi(2)=10.13; P=0.002) were significantly superior to placebo.
CONCLUSIONS: Sertraline is an effective treatment for generalised social phobia. Combined treatment with sertraline and exposure therapy, conducted by the general practitioner, may enhance the treatment efficacy in primary care.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435264     DOI: 10.1192/bjp.179.1.23

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  37 in total

1.  Algorithm for the pharmacotherapy of anxiety disorders.

Authors:  Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

2.  Combined pharmacotherapy and psychotherapy for social anxiety disorder.

Authors:  Dan J Stein; Jonathan C Ipser
Journal:  Curr Psychiatry Rep       Date:  2010-08       Impact factor: 5.285

3.  Second-generation antidepressants in social anxiety disorder: meta-analysis of controlled clinical trials.

Authors:  Gabriela Bezerra de Menezes; Evandro Silva Freire Coutinho; Leonardo F Fontenelle; Paula Vigne; Ivan Figueira; Márcio Versiani
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 4.  Social anxiety disorder : current treatment recommendations.

Authors:  Jacqueline E Muller; Liezl Koen; Soraya Seedat; Dan J Stein
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Efficacy and tolerability of second-generation antidepressants in social anxiety disorder.

Authors:  Richard A Hansen; Bradley N Gaynes; Gerald Gartlehner; Charity G Moore; Ruchi Tiwari; Kathleen N Lohr
Journal:  Int Clin Psychopharmacol       Date:  2008-05       Impact factor: 1.659

Review 6.  Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis.

Authors:  Winfried Rief; Yvonne Nestoriuc; Anna von Lilienfeld-Toal; Imis Dogan; Franziska Schreiber; Stefan G Hofmann; Arthur J Barsky; Jerry Avorn
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 7.  Anxiety in primary care.

Authors:  Kristen Hope Demertzis; Michelle G Craske
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

8.  Serotonin modulates anxiety-like behaviors during withdrawal from adolescent anabolic-androgenic steroid exposure in Syrian hamsters.

Authors:  Lesley A Ricci; Thomas R Morrison; Richard H Melloni
Journal:  Horm Behav       Date:  2012-09-28       Impact factor: 3.587

9.  D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder.

Authors:  Stefan G Hofmann; Jasper A J Smits; David Rosenfield; Naomi Simon; Michael W Otto; Alicia E Meuret; Luana Marques; Angela Fang; Candyce Tart; Mark H Pollack
Journal:  Am J Psychiatry       Date:  2013-07       Impact factor: 18.112

10.  Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder.

Authors:  C François; S A Montgomery; N Despiegel; S Aballéa; J Roïz; P Auquier
Journal:  Int J Clin Pract       Date:  2008-08-28       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.